Skip to main content
Xlife Sciences AG logo

Xlife Sciences AG — Investor Relations & Filings

Ticker · XLS ISIN · CH0461929603 LEI · 984500AH590BE88BB517 SW Professional, scientific and technical activities
Open in API
Filings indexed 287 across all filing types
Latest filing 2025-12-01 Regulatory Filings
Country CH Switzerland
Listing SW XLS

About Xlife Sciences AG

https://www.xlifesciences.ch/en/home

Xlife Sciences AG is a life sciences company that specializes in the value development and commercialization of early-stage research projects. The company identifies promising technologies from universities and other research institutions, acting as an incubator and accelerator to bridge the gap between academic research and healthcare markets. Its operations are focused on four core areas: technology platforms, biotechnologies and therapies, medical technology (health technology), and the application of artificial intelligence in life sciences and digital health. The primary objective is to develop solutions that address high unmet medical needs and improve quality of life.

Recent filings

Filing Released Lang Actions
Xlife Sciences AG Delivers Breakthrough in Early Alzheimers Detection, Unlocking Major Market Opportunity
Regulatory Filings Classification · 1% confidence The document is a press release issued by Xlife Sciences AG announcing a breakthrough in medical device certification (NeuroMex). It does not contain financial statements, proxy materials, or specific regulatory filings, but rather serves as a corporate news announcement regarding business operations and product development. As it does not fit into specific categories like earnings releases or reports, it falls under the general regulatory announcement category.
2025-12-01 English
Xlife Sciences AG Delivers Breakthrough in Early Alzheimer’s Detection, Unlocking Major Market Opportunity
Regulatory Filings Classification · 1% confidence The document is an 'ad hoc announcement' regarding clinical trial results for a medical device (NeuroMex). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a corporate governance or management change notice. As it is a general regulatory announcement regarding company news/developments, it falls under the 'Regulatory Filings' (RNS) category.
2025-12-01 English
Xlife Sciences AG erzielt Durchbruch bei der Früherkennung von Alzheimer und erschließt bedeutendes Marktpotenzial
Regulatory Filings Classification · 1% confidence The document is an 'Ad-hoc-Mitteilung' (Ad-hoc announcement) issued by Xlife Sciences AG regarding clinical study results for a medical device (NeuroMex). It follows the standard format of a corporate press release or regulatory news announcement (RNS) under Swiss exchange regulations (Art. 53 KR). It does not constitute a full financial report, proxy statement, or other specific filing type, but rather serves as a general regulatory disclosure of material corporate news.
2025-12-01 German
Xlife Sciences AG Provides Update on VERAXA Biotech AGs NASDAQ Listing Process Following U.S. Government Shutdown
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing an update on a portfolio company's (VERAXA Biotech AG) ongoing merger and NASDAQ listing process involving a SPAC (Voyager Acquisition Corp.). It discusses the status of a Form F-4 filing with the SEC and the timeline for an upcoming EGM. Since this is an announcement regarding M&A activity and the progress of a business combination, it falls under the M&A Activity category.
2025-11-28 English
Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown
M&A Activity Classification · 1% confidence The document is a press release issued by Xlife Sciences AG regarding the progress of a merger and listing process for its portfolio company, VERAXA Biotech AG. It discusses a business combination with a SPAC (Voyager Acquisition Corp.) and SEC filings. While it mentions M&A activity, it is primarily a corporate announcement regarding the status of a transaction rather than the legal merger agreement itself. Given the focus on the business combination and the update on the listing process, it falls under M&A Activity (TAR).
2025-11-28 English
Xlife Sciences AG gibt ein Update zum Stand des NASDAQ-Listing-Prozesses der VERAXA Biotech AG nach US-Regierungsstillstand bekannt
Regulatory Filings Classification · 1% confidence The document is a press release issued by Xlife Sciences AG regarding the progress of a merger and NASDAQ listing process for its portfolio company, VERAXA Biotech AG. It discusses the filing of an amended Form F-4 with the SEC following a US government shutdown. While it mentions M&A activity, it is primarily an update on the status of a transaction and regulatory process rather than the definitive merger agreement itself. Given the focus on corporate development and the announcement of a transaction status, it falls under M&A Activity (TAR).
2025-11-28 German

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.